Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Renal (urea and creatinine) (a, b) and Liver function (ALT and AST) (c, d) test in serums of different experimental groups and body weight changes (e) on day 10. by Omid Mehrpour (9385929)

Subjects:

(A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups. by Jie Liu (15128)

Subjects:

Hazard ratios for Sex across age based on unadjusted (A) and adjusted (B) Cox model. Note: shaded areas representing the 95% confidence intervals; green bars indicating the distrib... by Hui Ouyang (245739)

Subjects:

Comparison of phenotypes between adult control and <i>aP2-Drp1</i>^f/f mice. by Yuta Ibayashi (20404811)

Subjects:

<i>mMgat2</i> and <i>HuMgat2</i> mice become obese when fed a HFD. by J. Jose Corbalan (22439198)

Subjects:

Relative permeability curve of a well in Gudong test area. by Mengyun Li (7490870)

Subjects:

Photomicrographs of H&E-stained cerebellum sections from control and different pregnant mothers: control (A & B) and BM (C & D) groups, showing normal histological structure of the... by Amoura M. Abou-El-Naga (21001524)

Results for fibrin dominant clots: (A) time to recanalize <i>in vitro</i> model; (B) relative clot reduction; (C) RBC release; (D) relative clot degradation rate. by Sandra Thalerová (11434762)

Forest plot of the improvement in primary endpoints. by Jin-Min Gu (17915039)

Subjects:

Forest plot of inflammatory markers. by Jin-Min Gu (17915039)

Subjects:

Forest plot of the second endpoint of the clinical symptom improvement. by Jin-Min Gu (17915039)

Subjects:

PP1/PP2A does not dephosphorylate pS295 <i>in vitro</i>. by Takahiko Chimura (729098)

“…The decrease of phosphorylated GSK3β (pGSK3β(S9)) was completely suppressed by the PP1/PP2A inhibitor calyculin A. …”

Echogenic properties were assessed using a portable ultrasound, similar to the devices that are used clinically. by Bryan S. Margulies (21492667)

Subjects: